

6 Now listen to the meeting in which Karl (CEO), Fred (Head of Regulatory Affairs), and Caroline (Head of Pharmacovigilance) discuss the SAE and its implications for the company. Are the following statements true (✓) or false (x)?

- 1 ☐ There are two dosage forms of *Mensamint*TM currently on the market.
- 2 ☐ The serious adverse event is clearly linked to *Mensamint*TM.
- 3 ☐ The documentation for the new dosage form of *Mensamint*TM will be submitted to the authorities soon.
- 4 ☐ Heart trouble is a known side effect of *Mensamint*TM.

